


Anti-IFNA Recombinant Antibody Products

Anti-Ifna Products
- Human Anti-IFNA Antibody (clone mAb 01), mRNA (PABL-595-mRNA)
-
- Species Reactivity: Human
- Rat Anti-Ifna Recombinant Antibody (clone RMMA-1) (NEUT-957CQ)
-
- Species Reactivity: Mouse
- Type: Rat IgG1
- Application: ELISA, Neut
- Rat Anti-Ifna Recombinant Antibody (clone CBL982) (NEUT-956CQ)
-
- Species Reactivity: Mouse
- Type: Rat IgG1
- Application: ELISA, IP, Neut
- Rat Anti-Ifna Recombinant Antibody (clone CBL950) (NEUT-955CQ)
-
- Species Reactivity: Mouse
- Type: Rat IgG1
- Application: IHC, Neut
- Rat Anti-Ifna Recombinant Antibody (clone CBL934) (NEUT-954CQ)
-
- Species Reactivity: Mouse
- Type: Rat IgG1
- Application: ELISA, FC, Neut, WB
- Rat Anti-Ifna Recombinant Antibody (VMC185) (NEUT-953CQ)
-
- Species Reactivity: Mouse
- Type: Rat IgG1
- Application: Neut
- Hamster Anti-Ifna Recombinant Antibody (clone TIF-3C5) (NEUT-1069CQ)
-
- Species Reactivity: Mouse
- Type: Hamster IgG1
- Application: Block
-
- Species Reactivity: Human
- Type: Human IgG
- Application: WB, IHC, IF, FuncS
- Mouse Anti-IFNA Recombinant Antibody (clone DE-4) (MOB-0247MC)
-
- Species Reactivity: Chicken
- Type: Mouse IgG
- Application: WB, ELISA
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is committed to delivering high-quality anti-IFNA antibodies to support researchers in the biomedical field. Understanding the importance of precise antibodies in scientific advancements, we ensure our products meet rigorous quality and reliability standards. Our dedication to excellence enables researchers to access dependable tools, helping them drive meaningful discoveries in their studies.
IFNA: A Crucial Cytokine in Antiviral Defense and Immune Regulation
Interferon-alpha (IFNA) is a crucial cytokine belonging to the type I interferon family, primarily involved in antiviral defense and immune regulation. It is produced by various cell types, particularly plasmacytoid dendritic cells, in response to viral infections. IFNA binds to the interferon-alpha/beta receptor (IFNAR), activating the JAK-STAT signaling pathway, which leads to the transcription of interferon-stimulated genes (ISGs) that enhance the antiviral state of cells. Besides its antiviral properties, IFNA plays a role in modulating innate and adaptive immune responses, influencing T cell activation, natural killer (NK) cell function, and antigen presentation. Due to its immunomodulatory effects, IFNA has been widely studied and utilized in the treatment of viral infections, autoimmune diseases, and certain cancers, such as melanoma and hematological malignancies. However, excessive or prolonged IFNA activity is associated with inflammatory and autoimmune conditions, including systemic lupus erythematosus (SLE). As a critical immune regulator, IFNA remains a key target in therapeutic research, with ongoing studies focused on its modulation for clinical benefits.
Alternative Names
Interferon-α; IFN-α
Background
The IFN-α proteins are produced by leukocytes. They are mainly involved in innate immune response against viral infection. The genes responsible for their synthesis come in 13 subtypes that are called IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21. These genes are found together in a cluster on chromosome 9.
Anti-IFNA rAb Products
We are dedicated to offering premium anti-IFNA recombinant antibodies to support and advance research in target-related drug development. Our goal is to facilitate scientific discovery by providing reliable and high-performance products.
Cat. No. | Product Name | Target Species | Host Species | Applications |
PABL-595 | Human Anti-IFNA Recombinant Antibody (clone mAb 01) | Human | Human | WB; IHC; IF; FuncS |
MOB-0247MC | Mouse Anti-IFNA Recombinant Antibody (clone DE-4) | Chicken | Mouse | WB; ELISA |
NEUT-953CQ | Rat Anti-Ifna Recombinant Antibody (VMC185) | Mouse | Rat | Neut |
NEUT-954CQ | Rat Anti-Ifna Recombinant Antibody (clone CBL934) | Mouse | Rat | ELISA; FC; Neut; WB |
Customer Reviews

Human Anti-IFNA Recombinant Antibody (clone mAb 01)
(Cat#: PABL-595)

Mouse Anti-IFNA Recombinant Antibody (clone DE-4)
(Cat#: MOB-0247MC)
rAb Production
With extensive experience in expression vector design, cell line screening, and antibody purification, we provide end-to-end services from gene synthesis to antibody production. Our high-quality solutions enhance research in the biomedical field, ensuring reliability and efficiency throughout the process.
Featured Anti-IFNA Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.
Fig.2 Gram-scale recombinant antibody production.
rAb Modalities
Creative Biolabs is committed to providing diverse recombinant antibody formats tailored to various scientific applications, including basic research and drug discovery. Our antibodies are designed to meet the specific needs of researchers, ensuring high quality and reliability. By offering versatile solutions, we aim to support scientific innovation and contribute to the advancement of biomedical research.
Fig.3 Full Length Anti-IFNA Recombinant Antibody Production and Modalities.
Drug Information Targeting IFNA
Table 1. Therapeutic approaches targeting IFNA in clinical development.
Research phase | Company | Classification | Indications | Details |
Launched - 2021 |
AstraZeneca Bristol-Myers Squibb |
Biologics | Cutaneous lupus erythematosus; Inflammatory myopathy | This is a fully human antibody targeting the interferon alpha receptor 1 (IFNAR1). |
Launched - 2019 |
AOP Orphan PharmaEssentia |
Drug Conjugates | Chronic myeloid leukemia | it was launched for the treatment of adult patients with polycythemia vera. |
Launched - 2018 |
Genova Biotech (Beijing) Novagen |
Biologics | Cancer | It was launched in 2018 for the treatment of chronic hepatitis B. |
Launched - 2017 | Biocad | Biologics | Multiple sclerosis, relapsing-remitting | It was first launched in 2017 for the treatment of relapsing-remitting multiple sclerosis (RRMS). |
Launched - 2016 | Xiamen Amoytop Biotech | Drug Conjugates | Hepatitis B, chronic; Hepatitis C, chronic | The product was launched in 2016 for the treatment of chronic hepatitis C in adult patients. |
Launched - 2014 | Biogen | Drug Conjugates | Multiple sclerosis | This antibody was approved for the treatment of relapsing-remitting multiple sclerosis. |
Launched - 2013 | Biocad | Drug Conjugates | Hepatitis C (HCV) | It was launched in 2013 for the treatment of hepatitis C infection. |
Launched - 2011 | Cadila Healthcare | Drug Conjugates | Hepatitis B (HBV) | It was first launched in 2011 for the treatment of hepatitis B and C. |
Launched - 2007 | CinnaGen | Biologics | Multiple sclerosis | It is a recombinant glycosylated human interferon beta 1a; produced in CHO cells for the treatment of relapsing forms of multiple sclerosis (MS). |
If you would like to learn more about our anti-IFNA recombinant antibody products or have any questions, please feel free to contact us at any time. Our experienced team is committed to providing comprehensive support, offering expert guidance and tailored solutions to meet your specific research needs. We strive to ensure a seamless experience, helping you achieve reliable and impactful results in your scientific work. Your success is our priority, and we are always here to assist you.